|Bid||0.0000 x 1300|
|Ask||0.0000 x 2200|
|Day's Range||0.1600 - 0.1779|
|52 Week Range||0.1450 - 2.5400|
|Beta (5Y Monthly)||0.56|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 14, 2022 - Nov 18, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.00|
Subscribe to Yahoo Finance Plus to view Fair Value for VBLT
Axsome (AXSM) initiates a phase III open-label study for its pipeline candidate, AXS-07 for treating acute migraine.
Pliant (PLRX) receives a positive DSMB review of the ongoing mid-stage study evaluating the company's lead candidate PLN-74809 for treating idiopathic pulmonary fibrosis.
TEL AVIV, Israel and NEW YORK, Sept. 01, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), a biotechnology company developing targeted medicines for immune-inflammatory diseases, today announced that VBL received a written notification (the “Notification Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”) on August 31, 2022, notifying VBL that it is not in compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rules for continued listing on the Nasdaq.